Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:08 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 343 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Observation for safety Clear all

Conditions: Kidney Transplant
Interventions: Abatacept, Standard of Care at US Transplant Centers; Biological · Procedure
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 15
States / cities: Birmingham, Alabama • Los Angeles, California • New Haven, Connecticut + 11 more

Conditions: Chronic Spontaneous Urticaria
Interventions: LOU064 (blinded), Placebo, LOU064 (open label); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 696 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 43
States / cities: Birmingham, Alabama • Litchfield Park, Arizona • Little Rock, Arkansas + 38 more

Conditions: Asthma
Interventions: Omalizumab, Placebo; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 65 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Cystic Fibrosis
Interventions: IVA; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 0 Months to 24 Months
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 17
States / cities: Birmingham, Alabama • Palo Alto, California • Wilmington, Delaware + 14 more

Conditions: Head and Neck Cancer
Interventions: Not listed
Lead sponsor: Foundation for the National Institutes of Health; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 3
States / cities: Boston, Massachusetts • Houston, Texas

Conditions: Ras/MAPK Pathway Vascular Anomalies, Vascular Anomalies, Vascular Anomaly
Interventions: Trametinib; Drug
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 2 Months to 30 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Keratoconus; Post-Refractive Ectasia
Interventions: Corneal Tissue Addition Keratoplasty (CTAK); Procedure
Lead sponsor: Corneagen LLC; Other
Eligibility: Not listed
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 5
States / cities: Albuquerque, New Mexico • Fayetteville, North Carolina • Brecksville, Ohio + 2 more

Conditions: Chronic Heart Failure, CKD Stage 3
Interventions: AquaPass System; Device
Lead sponsor: AquaPass Medical Ltd.; Industry
Eligibility: 21 Years to 79 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 8
States / cities: La Jolla, California • San Francisco, California • Minneapolis, Minnesota + 5 more

Conditions: Pancreatic Cancer, Pancreas Cancer, Cancer of the Pancreas
Interventions: Personalized neoantigen DNA vaccine, TDS-IM Electrode Array System, Peripheral blood draws; Biological · Device · Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 2
States / cities: Baltimore, Maryland • St Louis, Missouri

Conditions: Fossa Ependymoma
Interventions: 5-Azacytidine and trastuzumab infusion; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 1 Year to 80 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Limbal Stem Cell Deficiency
Interventions: CSB-001 Ophthalmic Solution 0.1%; Biological
Lead sponsor: Claris Biotherapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 6
States / cities: Loma Linda, California • Carmel, Indiana • Indianapolis, Indiana + 3 more

Conditions: Hyperthermia
Interventions: Sauna Detoxification Protocol, Observation Sessions; Other
Lead sponsor: Bastyr University; Other
Eligibility: 21 Years to 35 Years
Enrollment: 1 participant
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Kenmore, Washington

Conditions: Chronic Spontaneous Urticaria
Interventions: Dupilumab; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 12 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Wilmington, North Carolina

Conditions: Melanoma, Head and Neck Squamous Cell Carcinoma, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Solid Tumor
Interventions: IPN01194; Drug
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 5
States / cities: Los Angeles, California • San Diego, California • New Haven, Connecticut + 2 more

Conditions: Thyroid Lobectomy
Interventions: Pre-Surgery Survey, Post-Surgery Surveys; Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Diabetic Macular Edema
Interventions: Faricimab, Ranibizumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 229 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 60
States / cities: Phoenix, Arizona • Tucson, Arizona • Fullerton, California + 53 more

Conditions: Osteoporosis, Postmenopausal
Interventions: Abaloparatide, Teriparatide; Drug
Lead sponsor: Radius Health, Inc.; Industry
Eligibility: 50 Years and older · Female only
Enrollment: 22,054 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Proliferative Diabetic Retinopathy (PDR)
Interventions: Aflibercept 8mg; Drug
Lead sponsor: Edward Wood, MD; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 3
States / cities: Austin, Texas • Bellaire, Texas • San Antonio, Texas

Conditions: Hepatitis C Infection, Viruses, Hepatocellular Carcinoma, Hepatitis, Viral, Human, Liver Cirrhosis
Interventions: Civacir® 10%; Biological
Lead sponsor: Biotest Pharmaceuticals Corporation; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 23
States / cities: Los Angeles, California • San Francisco, California • Miami, Florida + 15 more

Conditions: Active Non-segmental Vitiligo
Interventions: PF-06651600, placebo, PF06700841, narrow-band UVB phototherapy; Drug · Device
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 366 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 40
States / cities: Huntington Beach, California • Irvine, California • Los Angeles, California + 25 more

Conditions: Fecal Incontinence
Interventions: Not listed
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 277 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 20
States / cities: Scottsdale, Arizona • Los Angeles, California • Orange, California + 16 more

Conditions: Lymphoma
Interventions: Non-Interventional; Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 2
States / cities: Lawrenceville, New Jersey • Milwaukee, Wisconsin

Conditions: Hemophilia A, Hemophilia B
Interventions: PF-06741086; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years to 74 Years · Male only
Enrollment: 188 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 4
States / cities: Tampa, Florida • Iowa City, Iowa • New Hyde Park, New York + 1 more

Conditions: Ulcerative Colitis, Crohn's Disease
Interventions: Vedolizumab SC, No Intervention; Drug · Other
Lead sponsor: Takeda; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 13
States / cities: Phoenix, Arizona • Loma Linda, California • Orange, California + 9 more

Search by objective public record fields.

Assessment of Biomarker-Guided CNI Substitution In Kidney Transplantation

An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib

Sputum-derived Cellular Targets After Xolair (Omalizumab)

A Study to Evaluate the Safety of Long-term Ivacaftor Treatment in Participants With Cystic Fibrosis Who Are Less Than 24 Months of Age at Treatment Initiation and Have an Approved Ivacaftor-Responsive Mutation

A Prospective Observational Study to Evaluate Acute Kidney Injury Biomarkers In Patients Receiving First Cycle of Cisplatin Chemotherapy for Head and Neck Cancers

24VA021; VATCH Trametinib for Ras/MAPK Pathway VAs

Retrospective Study of Corneal Tissue Addition Keratoplasty for Keratoconus and Post-Refractive Ectasia

Reducing Fluid Overload in Heart Failure Patients Using a Non-invasive, Renal Independent System

Neoantigen DNA Vaccine in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy

Combination Intraventricular Chemotherapy Pilot Study: 5-Azacytidine (5-AZA) and Trastuzumab Infusions Into the Fourth Ventricle or Resection Cavity in Children and Adults with Recurrent or Residual Posterior Fossa Ependymoma

Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Subjects With Limbal Stem Cell Deficiency

Complementary and Alternative Medicine Sauna Detoxification Study: Phase I

A Study to Describe the Real-world Effectiveness, Safety and Patterns of Use of Dupilumab in Patients With Chronic Spontaneous Urticaria

A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours

A Randomized Control Trial for Patient Reported Outcomes and Safety in Outpatient Thyroid Lobectomy

A Study of Faricimab (RO6867461) in Participants With Center-Involving Diabetic Macular Edema

Real-world Effectiveness and Cardiovascular Safety Study of Abaloparatide in Postmenopausal Women

High Dose Eylea for Proliferative Diabetic Retinopathy Outcomes

Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.

A Phase 2b Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Active Non-segmental Vitiligo Subjects

Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)

Safety of Allogeneic Hematopoietic Cell Transplantation (HCT) For Patients With Classical Hodgkin Lymphoma (CHL) Treated With Nivolumab

Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B

A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)